Starting from the iron(II) complex, [(L1)FeII(CH3CN)2]+ (1), of the tris(2-pyridylthio)methanido (L1) ligand, an iron(II)-benzilate complex, [(L2)FeII(PyS)(benzilate)] (2), (L2 = bis(2-pyridylthio)carbene and PyS = pyridine-2-thiolate) was isolated and characterized. Single crystal X-ray diffraction studies of 2 reveal that the iron(II) center is coordinated by the carbene ligand (L2) in a tridentate N2C mode, along with a bidentate PyS formed upon C–S bond cleavage of L1. A solvent-dependent carbene-carbanion equilibrium for L1 is favored toward carbene in the presence of anionic benzilate in dichloromethane, leading to the formation of 2. Complex 2, upon reaction with dioxygen, undergoes a rearrangement of the carbene (L2) to carbanion (L1), ultimately affording an iron(III)-benzilate complex, [(L1)FeIII(benzilate)] (3). Intriguingly, the iron(III)-benzilate complex in the presence of complex 1 reacts with dioxygen, leading to complete decarboxylation of the coordinated benzilate. This observation suggested possible cooperative involvement of a dimeric intermediate in the reaction pathway. Consistent with this hypothesis, a benzilate-bridged mixed-valent diiron, [(L1)FeIII(benzilate)(L2)FeII(PyS)]+ (4), was isolated independently, and its dioxygen reactivity was evaluated. Expectedly, complex 4 undergoes quantitative decarboxylation upon reaction with dioxygen. These findings highlight the importance of solvent-dependent rearrangement capability of the carbanionic ligand in directing dioxygen activation and benzilate decarboxylation at the iron center.
No takes yet. Share an insight, caveat, or question.
Bhowmik et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: